Brief: Sensei Biotherapeutics Announces First Patient Dosed In Phase 1/2 Clinical Trial Of Sns-101, A Conditionally Active Vista-Blocking Antibody, For The Treatment Of Advanced Solid Tumors
01/06/2023 12:31
June 1 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE
1/2 CLINICAL TRIAL OF SNS-101, A CONDITIONALLY ACTIVE
VISTA-BLOCKING ANTIBODY, FOR THE TREATMENT OF ADVANCED SOLID
TUMORS
* SENSEI BIOTHERAPEUTICS INC - TOPLINE PHASE 1 MONOTHERAPY
AND
INITIAL COMBINATION DATA EXPECTED IN 2024
Source text for Eikon: ID:nGNX8lfRQS
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)